The Asia Pacific PCR technologies market is expected to grow from US$ 2.83 billion in 2022 to US$ 5.46 billion by 2030. It is estimated to record a CAGR of 8.6% from 2022 to 2030.
This is the first time that the US FDA has given such a classification to an IVD test for early diagnosis of stomach cancer, a molecular IVD test from Southeast Asia, and a blood miRNA test worldwide. Some companies have also increased their research and development funds for the enhancement of gene synthesis. In In 2022, Temasek contributed US $85 million to the healthtech business Molbio Diagnostics, located in India. Molbio designs portable diagnostic tools for a range of conditions, including HIV, dengue, malaria, hepatitis, and tuberculosis (TB). In 2021, in a Series E+ fundraising round, Ustar, a Chinese point-of-care (POC) business that creates molecular diagnostic tools, raised roughly US$ 2.6 million.
Ustar will use a portion of the funds raised to improve the effectiveness of their flagship high-throughput, completely automated nucleic acid amplification test instrument. The remaining funds will go into developing a next generation testing platform, increasing the variety of tests offered, and mass-producing polymerase chain reaction (PCR) testing kits for home usage.
Therefore, the increasing availability of financial support for research and development in disease-specific genomics propels the demand for PCR technologies.
The projected growth of the PCR technologies market in China during the forecast period is attributed to the increasing demand for high-quality healthcare products, growing prevalence of lifestyle diseases in the country, rising developments in diagnostics technologies, surging number of diagnostic centers and hospitals, and the ongoing modernization of medical facilities in hospitals. In China, PCR techniques are used for preimplantation genetic diagnosis (PGD), cancer treatment, and noninvasive prenatal testing (NIPT). According to the article "Rare Disease Day: why China's Rare Disease Burden Could Be an Opportunity for Innovation," published in February 2023, ~20 million Chinese people suffer from rare diseases.
PCR techniques such as dPCR and qPCR can be used in the diagnosis and treatment (to monitor treatment response) of such rare conditions. The rising prevalence of cancer in China also contributes to the PCR technologies market growth. According to the Global Cancer Observatory data, ~4.6 million cancer cases were reported in the country in 2020. In addition, cancer resulted in the death of 3.1 million people in China. China PCR Technologies Market Revenue and Forecast to 2030.US$ Mn) In terms of value, the PCR technologies market in China was valued at US$ 776.23 million in 2022 and is projected to reach US$ 1.54 billion by 2030; it is expected to register a CAGR of 9.00% during the forecast period.
Surging Investments and Funds Availability for PCR Technologies Boost Asia Pacific PCR Technologies Market
Government and federal agencies worldwide recognize the role of quantitative polymerase chain reaction (qPCR) and dPCR products in genome-based research in 2023, Mirxes, a leading innovator in RNA technology, specializes in accurate, non-invasive, and reasonably priced blood-based miRNA testing kits for early disease detection, particularly cancer, raised US $50 million in a Series D funding round. The company's main offering, GASTROClear, is an in vitro diagnostic test that uses PCR to detect stomach cancer early on. It has been designated as a Breakthrough Device by the US FDA.This is the first time that the US FDA has given such a classification to an IVD test for early diagnosis of stomach cancer, a molecular IVD test from Southeast Asia, and a blood miRNA test worldwide. Some companies have also increased their research and development funds for the enhancement of gene synthesis. In In 2022, Temasek contributed US $85 million to the healthtech business Molbio Diagnostics, located in India. Molbio designs portable diagnostic tools for a range of conditions, including HIV, dengue, malaria, hepatitis, and tuberculosis (TB). In 2021, in a Series E+ fundraising round, Ustar, a Chinese point-of-care (POC) business that creates molecular diagnostic tools, raised roughly US$ 2.6 million.
Ustar will use a portion of the funds raised to improve the effectiveness of their flagship high-throughput, completely automated nucleic acid amplification test instrument. The remaining funds will go into developing a next generation testing platform, increasing the variety of tests offered, and mass-producing polymerase chain reaction (PCR) testing kits for home usage.
Therefore, the increasing availability of financial support for research and development in disease-specific genomics propels the demand for PCR technologies.
Asia Pacific PCR Technologies Market Overview
The Asia Pacific PCR technologies market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in Asia Pacific is mainly attributed to the increasing foreign direct investments; the large availability of highly skilled, efficient workforces; and streamlining government policies resulting in high investments in the biotechnology sector. In addition, increasing cases of infectious and chronic diseases, and government and non-government initiatives fuel the growth of the PCR technologies market in Asia Pacific.The projected growth of the PCR technologies market in China during the forecast period is attributed to the increasing demand for high-quality healthcare products, growing prevalence of lifestyle diseases in the country, rising developments in diagnostics technologies, surging number of diagnostic centers and hospitals, and the ongoing modernization of medical facilities in hospitals. In China, PCR techniques are used for preimplantation genetic diagnosis (PGD), cancer treatment, and noninvasive prenatal testing (NIPT). According to the article "Rare Disease Day: why China's Rare Disease Burden Could Be an Opportunity for Innovation," published in February 2023, ~20 million Chinese people suffer from rare diseases.
PCR techniques such as dPCR and qPCR can be used in the diagnosis and treatment (to monitor treatment response) of such rare conditions. The rising prevalence of cancer in China also contributes to the PCR technologies market growth. According to the Global Cancer Observatory data, ~4.6 million cancer cases were reported in the country in 2020. In addition, cancer resulted in the death of 3.1 million people in China. China PCR Technologies Market Revenue and Forecast to 2030.US$ Mn) In terms of value, the PCR technologies market in China was valued at US$ 776.23 million in 2022 and is projected to reach US$ 1.54 billion by 2030; it is expected to register a CAGR of 9.00% during the forecast period.
Asia Pacific PCR Technologies Market Segmentation
The Asia Pacific PCR technologies market is segmented into technology, offerings, application, end user, and country.- Based on technology, the Asia Pacific PCR technologies market is segmented into real time PCR, conventional PCR, reverse transcription, digital PCR, multiplex RTPCR, hot start PCR, and others. The real time PCR segment held largest share of Asia Pacific PCR technologies market in 2022.
- In terms of offerings, the Asia Pacific PCR technologies market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share of Asia Pacific PCR technologies market in 2022. Further, reagents & consumables segment are categorized into reagents, vials size, and other consumables. Furthermore, vials size is segmented into 0.2ml to 2ml, 0.1 ml to 0.3 ml, 2 ml to 5ml, and other vials. Additionally, instruments segment is bifurcated into benchtop PCR, and portable thermocyclers/PCR.
- By application, the Asia Pacific PCR technologies market is segmented gene expression analysis, genetic sequencing, genotyping, nucleic acid synthesis, standard validation, point of care diagnostic application, environmental application, and others. The gene expression analysis segment held the largest share of Asia Pacific PCR technologies market in 2022.
- Based on end user, the Asia Pacific PCR technologies market is segmented hospitals & diagnostic centers, pharmaceutical & biotechnology companies, academic institutes & research laboratories, and others. The hospitals & diagnostic centers segment held the largest share of Asia Pacific PCR technologies market in 2022.
- By country, the Asia Pacific PCR technologies market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific PCR technologies market in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific PCR Technologies Market - Key Industry Dynamics
5. PCR Technologies Market - Asia Pacific Market Analysis
6. Asia Pacific PCR Technologies Market Analysis - By Technology
7. Asia Pacific PCR Technologies Market Analysis - By Offerings
8. Asia Pacific PCR Technologies Market Analysis - By Application
9. Asia Pacific PCR Technologies Market Analysis - By End User
10. Asia Pacific PCR Technologies Market -Country Analysis
11. PCR Technologies Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Thermo Fisher Scientific Inc
- Promega Corp
- QIAGEN NV
- bioMerieux SA
- Hoffmann-La Roche Ltd
- Bio-Rad Laboratories Inc
- Becton Dickinson and Co
- Takara Bio Inc
- Standard BioTools Inc
- Agilent Technologies Inc
- Ellume Ltd
